We are proud to announce the publication of an international survey conducted under the auspices of the Melanoma World Society – MWS, the EADO – European Association of Dermato-Oncology, and supported by HERACLIN GmbH. Featuring insights from 104 melanoma experts across 24 countries and 80+ institutions, this study sheds light on the adoption of neoadjuvant and perioperative therapies for melanoma metastases in clinical practice, providing key perspectives ahead of the NADINA Phase III results.

Key Findings:

• 89% of experts advocate for the immediate adoption of neoadjuvant or perioperative therapies for melanoma with locoregional metastases, even before regulatory approvals.
• The #SWOGS1801 regimen was identified as the preferred approach for immediate implementation, thanks to its established reimbursement and ease of application.
• 100% of respondents deemed these therapies safe for resectable locoregional disease (AJCC stage III).

This study highlights the importance of real-world data in shaping clinical guidelines and addressing regulatory and reimbursement challenges. We look forward to seeing how these findings evolve in light of the NADINA Phase III data!

Article link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00627-2/abstract